Figure 4 Approaches to targeting inhibitory immune receptors

Slides:

Advertisements

Similar presentations

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Advertisements

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

of different experimental arthritis models

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 5 Involvement of B cells in SLE

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Historical evolution of the clinical classification and

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Structure of TNF antagonists

Figure 1 Induction of immune tolerance

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

Figure 1 Four nodes to target when inducing anti-tumour immunity

Figure 2 Heat map of targeted therapies in autoimmune diseases

Figure 7 Clinical options for HCC therapy

Oncology Meets Immunology: The Cancer-Immunity Cycle

Figure 4 Involvement of SEMA4D in the pathogenesis

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Antinuclear antibodies and disease activity in SLE

Figure 5 Classification of immunotherapies

Figure 3 Transcriptome studies performed in the target

Figure 2 Shared genetic loci in systemic autoimmune diseases

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 7 Defects in apoptosis

Figure 3 Nucleic acid sensors in SLE

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 TNFSF activities enhancing immune cell activation

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 6 Combination therapy for HCC

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Strategies to achieve therapeutic inhibition of IL-1

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Rheumatol. doi: /nrrheum

Development of Next-Generation Immunomodulatory Antibodies for Cancer Therapy through Optimization of the IgG Framework Rienk Offringa, Martin J. Glennie

Figure 2 Overlap of associated loci among five rheumatic diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Influence of fucosylation on IgG effector functions

Figure 3 Effect of sialylated glycoforms on IgG activity

Figure 3 Multi-hit model for autoimmune diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 The role of CTLA4 and PD1 in T cell activation

Figure 2 Approaches to improve CAR-T-cell therapy

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Site of action of checkpoint inhibitors and agonists being

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Figure 1 Treat to target, remission and low disease activity in SLE

Figure 1 The current model of the pathogenesis of SLE

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Mechanisms of action of immunotherapy modalities

Figure 1 Chronic inflammation and DNA damage in people with SLE

Nat. Rev. Urol. doi: /nrurol

Figure 3 Underlying mechanisms of TREG cells in atherosclerosis

Figure 1 Patterns of joint and organ involvement in rheumatic disease

Figure 1 The role of macrophages in RA

Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;

Releasing the Brakes on Cancer Immunotherapy

Nat. Rev. Rheumatol. doi: /nrrheum

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

Figure 2 Involvement of plasmacytoid dendritic cells

Presentation transcript:

Figure 4 Approaches to targeting inhibitory immune receptors Figure 4 | Approaches to targeting inhibitory immune receptors. Multiple approaches are available to target immune checkpoints for the treatment of autoimmune rheumatic diseases. Specific examples of inhibitory receptors that have been targeted in preclinical and clinical studies are provided for each of the following approaches: soluble inhibitory-receptor–Fc fusion proteins (part a), ligand–Fc fusion proteins (part b), artificial ligands (part c), agonistic antibodies (part d), and bispecific antibodies (part e), which co-ligate an inhibitory and activating receptor. CIA, collagen-induced arthritis; CAIA, collagen-antibody-induced arthritis; CTLA4, cytotoxic T-lymphocyte-associated antigen 4; EAE, experimental autoimmune encephalomyelitis; EAU, experimental autoimmune uveoretinitis; FcγRIIB, low-affinity immunoglobulin-γ Fc region receptor IIb; PECAM1, platelet endothelial cell adhesion molecule; PILRα, paired immunoglobulin-like type 2 receptor-α; SLE, systemic lupus erythematosus; TIGIT, T-cell immunoreceptor with immunoglobulin and ITIM domains; VISTA, V-type immunoglobulin domain suppressor of T cell activation. van der Vlist, M. et al. (2016) Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us? Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2016.131